Income Statement Presentation 2023

2022: Core EPS development Roche Operations growth and accretion effect from share repurchase are main drivers for higher Core EPS CHF 20.05 +4.8% +4.8 p -1.6 p +3.1 p -1.5 p 2021 Operations 1 Ultomiris patent settl. + base effect 2021: Regeneron Profit Sharing Income² 21.02 Net accretion Novartis share repurchase 3 Other 4 2022 At Constant Exchange Rates (CER); 1 Core operating profit excluding impacts from Ultomiris patent settlement and Profit Sharing Income from Regeneron; 2 Net impact from the Ultomiris patent settlement: gross income, net of income tax and non-controlling interests and Profit Sharing Income from Regeneron, net of tax; ³ Impact of lower number of shares partially offset by increase in interest expense; 4 Other (net) include effects from changes in effective tax rate, gains/losses on equity securities, other financial income and expenses and non-controlling interests 58

View entire presentation